The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer.
Journal Article (Journal Article)
Forty-five patients have completed treatment with AFM, an intensive induction chemotherapy regimen composed of Adriamycin (doxorubicin, Adria Laboratories, Columbus, Ohio), 5-fluorouracil, and methotrexate with folinic acid rescue. This regimen was designed to produce rapid and extensive tumor shrinkage prior to high-dose alkylating agent chemotherapy with autologous marrow support. The overall response rate was 91%, and 38% of patients achieved complete clinical responses after a mean of 70 days on treatment. Hematologic and mucosal toxicity were extensive, but no toxic deaths were noted. AFM is a potent remission induction regimen for metastatic breast cancer, but its considerable toxicity suggests caution in its use for routine breast cancer treatment.
Full Text
Duke Authors
Cited Authors
- Jones, RB; Shpall, EJ; Shogan, J; Affronti, ML; Coniglio, D; Hart, L; Halperin, E; Iglehart, JD; Moore, J; Gockerman, J
Published Date
- August 1, 1990
Published In
Volume / Issue
- 66 / 3
Start / End Page
- 431 - 436
PubMed ID
- 2364358
International Standard Serial Number (ISSN)
- 0008-543X
Digital Object Identifier (DOI)
- 10.1002/1097-0142(19900801)66:3<431::aid-cncr2820660305>3.0.co;2-x
Language
- eng
Conference Location
- United States